| Incidence rates and predictors of diabetes in those with prediabetes: the Strong Heart Study. | |
| | |
MedLine Citation:
|
PMID: 20578203 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
BACKGROUND: The association between prediabetes as currently defined and incident diabetes in populations with widespread obesity, insulin resistance syndrome, and diabetes is not well defined. In this article, diabetes risk factors and incidence rates in American Indians (AI) with prediabetes are examined. METHODS: A total of 1677 AI who were nondiabetic at baseline was examined during a median 7.8-year follow-up as part of the Strong Heart Study (SHS). Risk factors for incident diabetes were measured. Prediabetes was defined according to American Diabetes Association 2003 criteria as having impaired glucose tolerance (IGT) (2-h plasma glucose [2-h PG] >or= 140 mg/dL but < 200 mg/dL) and/or impaired fasting glucose (IFG) (fasting plasma glucose [FPG] >or= 100 mg/dL but < 126 mg/dL). RESULTS: Prediabetes was identified by FPG alone in 87.5%. Diabetes incidence in those with baseline prediabetes was 66.1/1000 person-years, with a hazard ratio (HR) of 2.35 (95% conference interval: 1.84-3.01), compared with participants with normal glucose tolerance (NGT) at baseline. Elevated A(1c), 2-h PG, and fasting insulin (FI); albuminuria; and obesity were significantly associated with conversion from prediabetes to diabetes. Younger age, elevated FI (or body mass index [BMI] in models without FI), and less physical activity were significantly associated with conversion from NGT. CONCLUSIONS: Prediabetes is an independent predictor of conversion to type 2 diabetes in AI, and most can be identified through a fasting glucose measure. Measures of obesity, A(1c), FPG, 2-h PG, FI, albuminuria, and insulin resistance (IR) help predict this conversion. Obesity is a modifiable risk factor. Strategies to reduce obesity should be emphasized in individuals with prediabetes. |
| | |
Authors:
|
Hong Wang; Nawar M Shara; Darren Calhoun; Jason G Umans; Elisa T Lee; Barbara V Howard |
Related Documents
:
|
19855923 - Alanine-aminotransferase levels predict impaired glucose tolerance in a worksite popula... 20851483 - Short-term metabolic changes achieved by weight loss in hypertensive patients. 7667243 - Essential fatty acid deficiency prevents autoimmune diabetes in nonobese diabetic mice ... |
Publication Detail:
|
Type: Journal Article; Research Support, N.I.H., Extramural |
Journal Detail:
|
Title: Diabetes/metabolism research and reviews Volume: 26 ISSN: 1520-7560 ISO Abbreviation: Diabetes Metab. Res. Rev. Publication Date: 2010 Jul |
Date Detail:
|
Created Date: 2010-07-05 Completed Date: 2010-10-04 Revised Date: 2011-08-01 |
Medline Journal Info:
|
Nlm Unique ID: 100883450 Medline TA: Diabetes Metab Res Rev Country: England |
Other Details:
|
Languages: eng Pagination: 378-85 Citation Subset: IM |
Copyright Information:
|
Copyright (c) 2010 John Wiley & Sons, Ltd. |
Affiliation:
|
MedStar Health Research Institute, Hyattsville, MD, USA. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Aged Arizona / epidemiology Cohort Studies Diabetes Mellitus, Type 2 / epidemiology*, etiology Female Glucose Intolerance / epidemiology Humans Incidence Indians, North American / statistics & numerical data* Male Middle Aged North Dakota / epidemiology Obesity / complications Oklahoma / epidemiology Prediabetic State / epidemiology* Risk Factors South Dakota / epidemiology |
| Grant Support | |
ID/Acronym/Agency:
|
U01 HL041642-12/HL/NHLBI NIH HHS; U01 HL041642-13/HL/NHLBI NIH HHS; U01 HL041642-13S1/HL/NHLBI NIH HHS; U01 HL041642-14/HL/NHLBI NIH HHS; U01 HL041642-15/HL/NHLBI NIH HHS; U01 HL041642-15S1/HL/NHLBI NIH HHS; U01 HL041642-16/HL/NHLBI NIH HHS; U01 HL041642-17/HL/NHLBI NIH HHS; U01 HL041642-17S1/HL/NHLBI NIH HHS; U01 HL041642-18A1/HL/NHLBI NIH HHS; U01 HL041642-19/HL/NHLBI NIH HHS; U01 HL041642-19S1/HL/NHLBI NIH HHS; U01 HL041642-20/HL/NHLBI NIH HHS; U01 HL041654-12/HL/NHLBI NIH HHS; U01 HL041654-13/HL/NHLBI NIH HHS; U01 HL041654-14/HL/NHLBI NIH HHS; U01 HL041654-14S1/HL/NHLBI NIH HHS; U01 HL041654-15/HL/NHLBI NIH HHS; U01 HL041654-16/HL/NHLBI NIH HHS; U01 HL041654-17/HL/NHLBI NIH HHS; U01 HL041654-17S1/HL/NHLBI NIH HHS; U01 HL041654-18A1/HL/NHLBI NIH HHS; U01 HL041654-19/HL/NHLBI NIH HHS; U01 HL041654-20/HL/NHLBI NIH HHS; U01 HL041654-21/HL/NHLBI NIH HHS; U01-HL41642/HL/NHLBI NIH HHS; U01-HL41652/HL/NHLBI NIH HHS; U01-HL65520/HL/NHLBI NIH HHS; U01-HL65521/HL/NHLBI NIH HHS; UL01-HL41654/HL/NHLBI NIH HHS |
| Comments/Corrections | |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Effect of intensive insulin therapy on macular biometrics, plasma VEGF and its soluble receptor in n...
Next Document: Transcription factor 7-like 2 (TCF7L2) polymorphism and context-specific risk of impaired fasting gl...